治療抵抗性うつ病の管理─第二選択
表3.4 第二選択の治療法:一般的使用はより少なく,既報の文献での評価は様々である(好ましい順ではない)
治療 | 長所 | 短所 |
ケタミンを追加(0.5mg/kgを40分かけて静注)1 esketamine点鼻薬(ほとんどの国で既承認)の用量は28-84mg2 本Chapterのケタミン製剤に関する項を参照 |
|
|
ラモトリギンを追加 (100mg/日,200mg/日,400mg/日が使用されている)8 |
|
|
ECT10-12 |
|
|
tri-iodothyronine(T3)(20-50μg/日)を追加 より高用量でも安全に用いられている13-19 |
|
|
<編集協力者コメント>
ケタミンは,本邦では保険適用外である。
(桐野 創)
参照文献
- Marcantoni WS, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009-January 2019. J Affect Disord 2020; 277:831-841.
- Papakostas GI, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry 2020; 81:19r12889.
- Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 2018; 175:150-158.
- Witt K, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry 2020; 54:29-45.
- Beck K, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. JAMA Network Open 2020; 3:e204693.
- Aan Het Rot M, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67:139-145.
- Short B, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5:65-78.
- Goh KK, et al. Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. J Psychopharmacology 2019; 33:700-713.
- Papadimitropoulou K, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017; 33:701-711.
- Folkerts HW, et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study. Acta Psychiatr Scand 1997; 96:334-342.
- Gonzalez-Pinto A, et al. Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression. J Neuropsychiatry Clin Neurosci 2002; 14:206-209.
- Eranti S, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry 2007; 164:73-81.
- Joffe RT, et al. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32:241-251.
- Anderson IM. Drug treatment of depression: reflections on the evidence. Adv Psychiatric Treatment 2003; 9:11-20.
- Nierenberg AA, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519-1530.
- Iosifescu DV, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66:1038-1042.
- Abraham G, et al. T3 augmentation of SSRI resistant depression. J Affect Disord 2006; 91:211-215.
- Kelly TF, et al. Long term augmentation with T3 in refractory major depression. J Affect Disord 2009; 115:230-233.
- Parmentier T, et al. The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J Affect Disord 2018; 229:410-414.
- Garlow SJ, et al. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012; 46:1406-1413.